Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Semin Neurol 2007; 27(3): 211-220
DOI: 10.1055/s-2007-979683
DOI: 10.1055/s-2007-979683
Optic Neuritis
Edward J. Atkins1 , Valérie Biousse2 , 3 , Nancy J. Newman2 , 3 , 4- 1Division of Neurology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
- 2Department of Ophthalmology Surgery, Emory University School of Medicine, Atlanta, Georgia
- 3Department of Neurology Surgery, Emory University School of Medicine, Atlanta, Georgia
- 4Department of Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia
Further Information
Publication History
Publication Date:
18 June 2007 (online)
ABSTRACT
Optic neuritis is a common cause of visual loss in young patients. Visual function generally spontaneously improves over weeks, and 95% of patients return to visual acuity of at least 20/40 within 12 months. The initial magnetic resonance imaging (MRI) helps stratify the risk of multiple sclerosis in patients with acute isolated optic neuritis. High-dose steroids hasten the rate, but not the final extent, of visual recovery in optic neuritis, and the decision to use this therapy is individualized. Interferon therapy should be considered in selected high-risk patients.
KEYWORDS
Optic neuritis - multiple sclerosis clinically isolated syndrome - optic neuritis treatment trial
REFERENCES
- 1 Purvin V A. Optic neuropathies for the neurologist. Semin Neurol. 2000; 20 97-110
- 2 Frohman E M, Frohman T C, Zee D S et al.. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005; 4 111-121
- 3 Miller D, Barkhof F, Montalban X, Thompson A, Filipi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4 281-288
- 4 Miller D, Barkhof F, Montalban X, Thompson A, Filipi M. Clinically isolated syndromes suggestive of multiple sclerosis, part II: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005; 4 341-348
- 5 Arnold A C. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005; 139 1101-1108
- 6 Rizzo J F, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991; 109 1668-1672
- 7 Ebers G C. Optic neuritis and multiple sclerosis. Arch Neurol. 1985; 42 702-704
- 8 Kurtzke J F. Optic neuritis or multiple sclerosis. Arch Neurol. 1985; 42 704-710
- 9 Francis D A, Compston D A, Batchelor J R, McDonald W I. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry. 1987; 50 758-765
- 10 Miller D H, Ormerod I EC, McDonald W I et al.. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry. 1988; 51 1569-1571
- 11 Rizzo J F, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology. 1988; 38 185-190
- 12 Söderström M, Jin Y P, Hillert J, Link H. Optic neuritis, prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998; 50 708-714
- 13 Ghezzi A, Martinelli V, Torri V et al.. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999; 246 770-775
- 14 Brex P A, Ciccarelli O, O'Riordan J I et al.. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002; 346 158-164
- 15 Tintoré M, Rovira A, Rio J et al.. Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann Neurol. 2005; 57 210-215
- 16 Beck R W, Cleary P A, Anderson Jr M M et al.. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326 581-588
- 17 Optic Neuritis Study Group . Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1997; 115 1545-1552
- 18 Optic Neuritis Study Group . Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol. 2004; 137 77-83
- 19 Optic Neuritis Study Group . The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology. 1997; 49 1404-1413
- 20 Optic Neuritis Study Group . Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004; 61 1538-1541
- 21 Optic Neuritis Study Group . High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003; 121 944-949
- 22 Optic Neuritis Study Group . Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004; 61 1386-1389
- 23 Beck R W, Cleary P A, Trobe J D et al.. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993; 329 1764-1769
- 24 Beck R W, Arrington J, Murtagh F R et al.. Brain magnetic resonance imaging in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol. 1993; 50 841-846
- 25 Jacobs L D, Beck R W, Simon J H et al.. Intramuscular interferon beta-1a treatment initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000; 343 898-904
- 26 CHAMPS Study Group . Interferon β-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001; 132 463-471
- 27 Beck R W, Chandler D L, Cole S R et al.. Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002; 51 481-490
- 28 CHAMPIONS Study Group . IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006; 66 678-684
- 29 Comi G, Filippi M, Barkhof F et al.. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study (ETOMS). Lancet. 2001; 357 1576-1582
- 30 Kappos L, Polman C, Freedman M et al.. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006; 67 1242-1249
- 31 Brusaferri F, Candelise F. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000; 247 435-442
- 32 Kaufman D I, Trobe J D, Eggenberger E R et al.. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology. 2000; 54 2039-2044
- 33 Sellebjerg F, Nielsen H S, Frederiksen J L, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999; 52 1479-1484
- 34 Morrissey S P, Miller D H, Kendall B E et al.. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain. 1993; 116 135-146
- 35 Sandberg-Wollheim M, Bynke H, Cronqvist S et al.. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990; 27 386-393
- 36 Jacobs L D, Kaba S E, Miller C M et al.. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol. 1997; 41 392-398
- 37 Nilsson P, Larsson E M, Maly-Sundgren P et al.. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005; 252 396-402
- 38 Jin Y P, de Pedro-Cuesta J, Huang Y H, Söderström M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler. 2003; 9 135-141
- 39 Minneboo A, Barkhof F, Polman C H et al.. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004; 61 217-221
- 40 Tintoré M, Rovira A, Martinez M J et al.. Isolated demyelinating syndromes: comparison of different diagnostic MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000; 21 702-706
- 41 Korteweg T, Tintoré M, Uitdehaag B et al.. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006; 5 221-227
- 42 Barkhof F, Filippi M, Miller D H et al.. Isolated demyelinating syndromes: comparison of different magnetic resonance imaging criteria to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120 2059-2069
- 43 McDonald W I, Compston A, Edam G et al.. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50 121-127
- 44 Polman C H, Reingold S C, Edan G et al.. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005; 58 840-846
- 45 Dalton C M, Brex P A, Miszkiel K A et al.. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol. 2003; 53 673-676
- 46 Weinshenker B G, Bass B, Rice G P et al.. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989; 112 133-146
- 47 Dalton C M, Brex P A, Miszkiel K A et al.. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry. 2003; 74 1577-1580
- 48 Frederiksen J L. Can CSF predict the course of optic neuritis?. Mult Scler. 1998; 4 132-135
- 49 Rolak L A, Beck R W, Paty D W et al.. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology. 1996; 46 368-372
- 50 Cole S R, Beck R W, Moke P S et al.. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology. 1998; 51 885-887
- 51 Masjuan J, Alvarez-Cermeno J C, Garcia-Barragan N et al.. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006; 66 576-578
- 52 Achiron A, Kishner I, Sarova-Pinhas I et al.. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2004; 61 1515-1520
- 53 Sorensen P S, Wanscher B, Jensen C V et al.. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998; 50 1273-1281
- 54 Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol. 2002; 9 565-572
- 55 Roed H G, Langkilde A, Sellebjerg F et al.. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005; 64 804-810
- 56 Revesz T. Axonal lesions in MS: an old story revisited. Brain. 2000; 123 203-204
- 57 De Stefano N, Narayanan S, Francis G S et al.. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001; 58 65-70
- 58 Filippi M, Tortorella C, Rovaris M et al.. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000; 68 157-161
- 59 Bermel R A, Puli S R, Rudick R A et al.. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol. 2005; 62 1371-1376
- 60 Frohman E M, Racke M, van Den Noort S. To treat or not to treat? The therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Arch Neurol. 2000; 57 930-932
- 61 Balcer L J. Clinical practice: optic neuritis. N Engl J Med. 2006; 354 1273-1280
- 62 Montalban X. The pros and cons of early treatment of relapsing forms of multiple sclerosis. J Neurol. 2004; 251(suppl 4) IV30-IV34
- 63 van Engelen B G, Hommes O R, Pinckers A et al.. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol. 1992; 32 834-835
- 64 Rodriguez M, Lennon V A. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol. 1990; 27 12-17
- 65 Rodriguez M, Miller D J. Immune promotion of central nervous system remyelination. Prog Brain Res. 1994; 103 343-355
- 66 van Engelen B G, Miller D J, Pavelko K D et al.. Promotion of remyelination by polyclonal immunoglobulin and IVIg in Theiler's virus-induced demyelination and in MS. J Neurol Neurosurg Psychiatry. 1994; 57(suppl 1) 65-68
- 67 Rodriguez M, Miller D J, Lennon V A. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology. 1996; 46 538-545
- 68 Noseworthy J H, O'Brien P C, Petterson T M et al.. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001; 56 1514-1522
- 69 Boomer J A, Siatkowski R M. Optic neuritis in adults and children. Semin Ophthalmol. 2003; 18 174-180
- 70 Brady K M, Brar A S, Lee A G et al.. Optic neuritis in children: clinical features and visual outcome. J AAPOS. 1999; 3 98-103
- 71 Morales D S, Siatkowski R M, Howard C W, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus. 2000; 37 254-259
- 72 Lucchinetti C F, Kiers L, O'Duffy A et al.. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology. 1997; 49 1413-1418
Valérie BiousseM.D.
Neuro-Ophthalmology Unit, Emory Eye Center
1365-B Clifton Road NE, Atlanta, GA 30322